Cite as:

Altıner S, Çolak S, Çerçi P, Inal A, Keskin K. Interleukin-27 in Takayasu Arteritis: Serum Levels and Relationship with Disease Activity. Med J Eur. 2024;2(2):41-45. doi: 10.5281/zenodo.10706940

ABSTRACT

This study aimed to investigate the serum levels of interleukin-27 (IL-27) in patients with Takayasu arteritis (TA) and evaluate its role in determining disease activity. A total of 34 patients with TA (32 female, 2 male) and 34 healthy controls (32 female, 2 male) were enrolled.  Patients with TA were divided into two groups: active and inactive, according to Kerr scores. Twenty-one patients were in active group (mean age; 27.1 ± 6.9 years, mean disease duration 7.2±2.8 years) and 13 patients were in inactive group (mean age; 32.7 ± 5.3 years, mean disease duration; 8.7±4.1 years). Serum IL-27 levels were determined by ELISA. The mean serum IL-27 levels were 19.7±4.8 pg/ml in healthy controls, 128.3±11.7 pg/ml in active group, and 45.2±9.5 pg/ml in inactive group. Serum IL-27 levels in patients with TA were significantly higher than in healthy controls (p<0.001). Serum IL-27 levels were significantly higher in active group compared with inactive group (p<0.001). Both in active and inactive groups, there was a statistically significant correlation between serum IL-27 and serum CRP and ESR (r=0.588, p <0.001, r=0.503, p <0.001 and r=0.474, p <0.01, r=0.446, p <0.01, respectively). Biomarker studies in TA are mainly focused on differentiating active stage from inactive stage. The serum level of IL-27 may be a potential biomarker, which is associated with disease activity in patients with TA.

Keywords

Smoking, healthcare staff, knowledge, attitude.

REFERENCES

1. Kim ESH, Beckman J. Takayasu arteritis: challenges in diagnosis and management. Heart. 2018;104:558-565.
2. Alnabwani D, Patel P, Kata P, Patel V, Okere A, Cheriyath P. The Epidemiology and Clinical Manifestations of Takayasu Arteritis: A Descriptive Study of Case Reports. Cureus. 2021;13:e17998.
3. Onen F, Akkoc N. Epidemiology of Takayasu arteritis. Presse medicale. 2017;46:e197-e203.
4. Makin K, Isbel M, Nossent J. Frequency, presentation, and outcome of Takayasu arteritis in Western Australia. Mod Rheumatol. 2017;27:1019-1023.
5. Weyand CM, Watanabe R, Zhang H, Akiyama M, Berry GJ, Goronzy JJ. Cytokines, growth factors and proteases in medium and large vessel vasculitis. Clin Immunol. 2019;206:33-41.
6. Watanabe R, Berry GJ, Liang DH, Goronzy JJ, Weyand CM. Cellular Signaling Pathways in Medium and Large Vessel Vasculitis. Front Immunol. 2020;11:587089.
7. Charlot-Rabiega P, Bardel E, Dietrich C, Kastelein R, Devergne O. Signaling events involved in interleukin 27 (IL-27)-induced proliferation of human naive CD4+ T cells and B cells. The Journal of biological chemistry. 2011;286:27350-27362.
8. Neufert C, Becker C, Wirtz S, et al. IL-27 controls the development of inducible regulatory T cells and Th17 cells via differential effects on STAT1. European journal of immunology. 2007;37:1809-1816.
9. Stumhofer JS, Hunter CA. Advances in understanding the anti-inflammatory properties of IL-27. Immunol Lett. 2008;117:123-130.
10. Qiu SL, Sun QX, Zhou JP, et al. IL-27 mediates anti-inflammatory effect in cigarette smoke induced emphysema by negatively regulating IFN-gamma producing cytotoxic CD8(+) T cells in mice. European journal of immunology. 2021.
11. Alibaz-Oner F, Yentur SP, Saruhan-Direskeneli G, Direskeneli H. Serum cytokine profiles in Takayasu’s arteritis: search for biomarkers. Clinical and experimental rheumatology. 2015;33:S-32-35.
12. Kong X, Sun Y, Ma L, et al. The critical role of IL-6 in the pathogenesis of Takayasu arteritis. Clinical and experimental rheumatology. 2016;34:S21-27.
13. Gao Q, Lv N, Dang A, Li Z, Ye J, Zheng D. Association of interleukin-6 and interleukin-10 expression, gene polymorphisms, and Takayasu arteritis in a Chinese Han population. Clinical rheumatology. 2019;38:143-148.
14. Arend WP, Michel BA, Bloch DA, et al. The American College of Rheumatology 1990 criteria for the classification of Takayasu arteritis. Arthritis and rheumatism. 1990;33:1129-1134.
15. Kerr GS, Hallahan CW, Giordano J, et al. Takayasu arteritis. Ann Intern Med. 1994;120:919-929.
16. Hata A, Noda M, Moriwaki R, Numano F. Angiographic findings of Takayasu arteritis: new classification. International journal of cardiology. 1996;54 Suppl:S155-163.
17. Keser G, Aksu K, Direskeneli H. Takayasu arteritis: an update. Turk J Med Sci. 2018;48:681-697.
18. Nakaoka Y, Isobe M, Takei S, et al. Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis. 2018;77:348-354.
19. Nakaoka Y, Isobe M, Tanaka Y, et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology. 2020;59:2427-2434.
20. Singh A, Danda D, Hussain S, et al. Efficacy and safety of tocilizumab in treatment of Takayasu arteritis: A systematic review of randomized controlled trials. Mod Rheumatol. 2021;31:197-204.
21. Gon Y, Yoshifuji H, Nakajima T, et al. Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab. Mod Rheumatol. 2021;31:678-683.
22. Tripathy NK, Sinha N, Nityanand S. Interleukin-8 in Takayasu’s arteritis: plasma levels and relationship with disease activity. Clinical and experimental rheumatology. 2004;22:S27-30.
23. Misra DP, Chaurasia S, Misra R. Increased Circulating Th17 Cells, Serum IL-17A, and IL-23 in Takayasu Arteritis. Autoimmune Dis. 2016;2016:7841718.
24. Seringec Akkececi N, Yildirim Cetin G, Gogebakan H, Acipayam C. The C-Reactive Protein/Albumin Ratio and Complete Blood Count Parameters as Indicators of Disease Activity in Patients with Takayasu Arteritis. Medical science monitor : international medical journal of experimental and clinical research. 2019;25:1401-1409.
25. Rajaiah R, Puttabyatappa M, Polumuri SK, Moudgil KD. Interleukin-27 and interferon-gamma are involved in regulation of autoimmune arthritis. The Journal of biological chemistry. 2011;286:2817-2825.
26. Cao Y, Doodes PD, Glant TT, Finnegan A. IL-27 induces a Th1 immune response and susceptibility to experimental arthritis. Journal of immunology. 2008;180:922-930.
27. Tang Y, Bai Z, Qi J, et al. Altered peripheral B lymphocyte homeostasis and functions mediated by IL-27 via activating the mammalian target of rapamycin signaling pathway in patients with rheumatoid arthritis. Clin Exp Immunol. 2021;206:354-365.
28. Yoshizaki A, Yanaba K, Iwata Y, et al. Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation. Ann Rheum Dis. 2011;70:194-200.
29. Lee MH, Gallo PM, Hooper KM, et al. The cytokine network type I IFN-IL-27-IL-10 is augmented in murine and human lupus. Journal of leukocyte biology. 2019;106:967-975.
30. Cui X, Jiao C, Wang D, et al. Elevated Levels of IL-27 Are Associated with Disease Activity in Patients with Crohn’s Disease. Mediators of inflammation. 2021;2021:5527627.
31. Yoon T, Ahn SS, Pyo JY, et al. Predictive Ability of Serum IL-27 Level for Assessing Activity of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Mediators of inflammation. 2021;2021:6668884.
32. Qi J, Zhang Z, Tang X, Li W, Chen W, Yao G. IL-27 Regulated CD4(+)IL-10(+) T Cells in Experimental Sjogren Syndrome. Front Immunol. 2020;11:1699.
33. Ali YBM, El-Akhras BA, El-Shazly R, Bassyouni IH. Genetic polymorphisms of IL-27 and risk of systemic lupus erythematosus disease in the Egyptian population. Clinical rheumatology. 2021;40:4899-4907.
34. Gholijani N, Daryabor G, Kalantar K, et al. Interleukin-27 gene variant rs153109 is associated with enhanced cytokine serum levels and susceptibility to Behcet’s disease in the Iranian population. European cytokine network. 2020;31:140-146.

MJE-025